-- G Mining Ventures (GMIN.TO) 週二發布了其全資擁有的圭亞那 Oko West 金礦項目截至 2026 年第一季的最新進展。該公司表示,該項目持續按計劃和預算推進,預計將於 2027 年下半年實現首次黃金澆鑄,並於 2028 年 1 月開始商業化生產。 該公司表示,自 2025 年 10 月啟動開發活動以來,在工程、採購、場地基礎設施和選礦廠建設方面取得了顯著進展,同時提高了成本可見度和執行確定性。安全績效“仍然強勁”,迄今僅記錄到一起工時損失事故,總可記錄事故頻率為 0.37。 該公司還報告稱,根據已掙值計算,該項目整體進度已達 19.7%,建設工作正按計畫推進。迄今已支出約 2.92 億美元,承諾投資額為 5.25 億美元。 該項目仍保持在預算範圍內。詳細的工程和採購工作已完成約 80%。 該公司補充道,Oko West 2026 年和 2027 年的總資本支出預期維持不變,分別為 5.14 億美元至 5.68 億美元和 2.17 億美元至 2.4 億美元。基礎設施詳細設計計劃於 2026 年第二季完成,製程裝置的詳細工程設計已完成 70%。 週一,該公司股票在多倫多證券交易所收盤下跌 0.7%,報 47 美元。
Related Articles
Citigroup Adjusts Price Target on Marathon Petroleum to $257 From $243, Maintains Neutral Rating
Marathon Petroleum (MPC) has an average rating of overweight and mean price target of $253.25, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $256.58, Change: $+4.04, Percent Change: +1.60%
Research Alert: Peg Reports Strong Q1 Beat; On Track For $4.2b Capex And 7% Eps Growth In 2026
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:PEG reported Q1 2026 adjusted EPS of $1.55 vs. $1.43 (+8.4% Y/Y, +8.5% vs. consensus), supported by higher PSE&G margins from regulated infrastructure investments and customer growth, partially offset by higher depreciation and interest expense. PSEG Power earnings increased due to higher realized power prices and lower O&M costs, offset by lower generation volumes. We see the company as on target for $4.2B full-year 2026 capex guidance after deploying ~$0.8B in Q1, while PEG maintained long-term targets including $24B-$28B total capex for 2026-2030 and a 6%-7.5% rate base CAGR. Management reaffirmed its 2026 EPS guidance of $4.28-$4.40, representing ~7% growth at the midpoint. Both residential electric and gas customers increased ~1% on a trailing-12-month basis, which we think reflects continued execution of the regulated investment program. Annualized dividends were increased ~6% to $2.68 for 2026. We view this as a competitive growth rate amongst Multi-Utility peers.
Merck Completes Terns Pharmaceuticals Acquisition
Merck (MRK) said Tuesday it has completed the acquisition of Terns Pharmaceuticals after a cash tender offer at $53 per share.Terns' stock will no longer be listed on Nasdaq, it said.The deal will result in a charge to research and development expense of about $2.35 per share, included in Q2 and full year 2026 GAAP and non-GAAP results, Merck said.GAAP and non-GAAP EPS are also expected to take a hit of about $0.12 a share in 2026 on costs associated with advancing TERN-701 and costs of financing, it added.Price: $113.21, Change: $+0.10, Percent Change: +0.09%